Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

MicroRNA-150 functions as an antioncogenic regulator in osteosarcoma.

Xu J, Wang Z, Liao Z, Dai D, Ma X.

Oncol Lett. 2017 Aug;14(2):2483-2490. doi: 10.3892/ol.2017.6393. Epub 2017 Jun 16.

2.

Conventional osteosarcoma of the mandible successfully treated with radical surgery and adjuvant chemotherapy after responding poorly to neoadjuvant chemotherapy: a case report.

Kimura Y, Tomihara K, Tachinami H, Imaue S, Nakamori K, Fujiwara K, Suzuki K, Yasuda T, Miwa S, Nakayama E, Noguchi M.

J Med Case Rep. 2017 Aug 2;11(1):210. doi: 10.1186/s13256-017-1386-0.

3.

Reassessment of alkaline phosphatase as serum tumor marker with high specificity in osteosarcoma.

Kim SH, Shin KH, Moon SH, Jang J, Kim HS, Suh JS, Yang WI.

Cancer Med. 2017 Jun;6(6):1311-1322. doi: 10.1002/cam4.1022. Epub 2017 May 11.

4.

Overcoming Therapeutic Resistance of Bone Sarcomas: Overview of the Molecular Mechanisms and Therapeutic Targets for Bone Sarcoma Stem Cells.

Fujiwara T, Ozaki T.

Stem Cells Int. 2016;2016:2603092. doi: 10.1155/2016/2603092. Epub 2016 Dec 27. Review.

5.

STAT3 inhibitor, cucurbitacin I, is a novel therapeutic agent for osteosarcoma.

Oi T, Asanuma K, Matsumine A, Matsubara T, Nakamura T, Iino T, Asanuma Y, Goto M, Okuno K, Kakimoto T, Yada Y, Sudo A.

Int J Oncol. 2016 Dec;49(6):2275-2284. doi: 10.3892/ijo.2016.3757. Epub 2016 Nov 3.

6.

B7-H3 protein expression in a murine model of osteosarcoma.

Zhao JL, Chen FL, Zhou Q, Pan W, Wang XH, Xu J, Zhang SX, Ni LI, Yang HL.

Oncol Lett. 2016 Jul;12(1):383-386. Epub 2016 Jun 2.

7.

SERUM VALUES OF ALKALINE PHOSPHATASE AND LACTATE DEHYDROGENASE IN OSTEOSARCOMA.

Zumárraga JP, Baptista AM, Rosa LP, Caiero MT, Camargo OP.

Acta Ortop Bras. 2016 May-Jun;24(3):142-6. doi: 10.1590/1413-785220162403157033.

8.

L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer.

Biteau K, Guiho R, Chatelais M, Taurelle J, Chesneau J, Corradini N, Heymann D, Redini F.

Am J Cancer Res. 2016 Feb 15;6(3):677-89. eCollection 2016.

9.

Assessing the Prognostic Significance of Histologic Response in Osteosarcoma: A Comparison of Outcomes on CCG-782 and INT0133-A Report From the Children's Oncology Group Bone Tumor Committee.

Bishop MW, Chang YC, Krailo MD, Meyers PA, Provisor AJ, Schwartz CL, Marina NM, Teot LA, Gebhardt MC, Gorlick R, Janeway KA, Chou AJ.

Pediatr Blood Cancer. 2016 Oct;63(10):1737-43. doi: 10.1002/pbc.26034. Epub 2016 Apr 29.

10.

IS THERE ANY DIFFERENCE IN THE PROGNOSIS FOR PATIENTS WITH PRIMARY OSTEOSARCOMA WITH A POOR RESPONSE TO NEOADJUVANT CHEMOTHERAPY BETWEEN HUVOS GRADES I AND II?

Bispo Júnior RZ, Camargo OP.

Rev Bras Ortop. 2015 Nov 17;46(4):420-3. doi: 10.1016/S2255-4971(15)30256-1. eCollection 2011 Jul-Aug.

11.

Mesenchymal stem cells increase proliferation but do not change quiescent state of osteosarcoma cells: Potential implications according to the tumor resection status.

Avril P, Le Nail LR, Brennan MÁ, Rosset P, De Pinieux G, Layrolle P, Heymann D, Perrot P, Trichet V.

J Bone Oncol. 2015 Dec 12;5(1):5-14. doi: 10.1016/j.jbo.2015.11.002. eCollection 2016 Mar.

12.

Analysis of Prognostic Factors in High-Grade Osteosarcoma of the Extremities in Children: A 15-Year Single-Institution Experience.

Vasquez L, Tarrillo F, Oscanoa M, Maza I, Geronimo J, Paredes G, Silva JM, Sialer L.

Front Oncol. 2016 Feb 2;6:22. doi: 10.3389/fonc.2016.00022. eCollection 2016.

13.

The efficacy of high-dose versus moderate-dose chemotherapy in treating osteosarcoma: a systematic review and meta-analysis.

Wang WG, Wan C, Liao GJ.

Int J Clin Exp Med. 2015 Sep 15;8(9):15967-74. eCollection 2015.

14.

Osteosarcoma of the larynx.

Sawicki P, Każmierczak W, Szylberg Ł, Marszałek A.

Contemp Oncol (Pozn). 2015;19(3):246-9. doi: 10.5114/wo.2015.52659. Epub 2015 Jul 8.

15.

High-grade focal areas in low-grade central osteosarcoma: high-grade or still low-grade osteosarcoma?

Righi A, Paioli A, Dei Tos AP, Gambarotti M, Palmerini E, Cesari M, Marchesi E, Donati DM, Picci P, Ferrari S.

Clin Sarcoma Res. 2015 Oct 29;5:23. doi: 10.1186/s13569-015-0038-7. eCollection 2015.

16.

Transcriptional Profiling Identifies the Signaling Axes of IGF and Transforming Growth Factor-b as Involved in the Pathogenesis of Osteosarcoma.

Yang R, Piperdi S, Zhang Y, Zhu Z, Neophytou N, Hoang BH, Mason G, Geller D, Dorfman H, Meyers PA, Healey JH, Phinney DG, Gorlick R.

Clin Orthop Relat Res. 2016 Jan;474(1):178-89.

17.

The Variability in Surgical Margin Reporting in Limb Salvage Surgery for Sarcoma.

Hoang K, Gao Y, Miller BJ.

Iowa Orthop J. 2015;35:181-6. Review.

18.

Osteosarcoma: Current Treatment and a Collaborative Pathway to Success.

Isakoff MS, Bielack SS, Meltzer P, Gorlick R.

J Clin Oncol. 2015 Sep 20;33(27):3029-35. doi: 10.1200/JCO.2014.59.4895. Epub 2015 Aug 24. Review.

19.

Diagnostic assessment of osteosarcoma chemoresistance based on Virtual Clinical Trials.

Rejniak KA, Lloyd MC, Reed DR, Bui MM.

Med Hypotheses. 2015 Sep;85(3):348-54. doi: 10.1016/j.mehy.2015.06.015. Epub 2015 Jun 24.

20.

Species differences in tumour responses to cancer chemotherapy.

Lawrence J, Cameron D, Argyle D.

Philos Trans R Soc Lond B Biol Sci. 2015 Jul 19;370(1673). pii: 20140233. doi: 10.1098/rstb.2014.0233. Review.

Supplemental Content

Support Center